• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Friday 11/16/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

clinical stage

  • 4:42 PM

    LAGUNA HILLS, Calif., Nov. 29, 2016, PMCB, (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that a Pre-Investigational New Drug (Pre-IND) meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has been granted by the FDA. During the meeting with representatives from CBER, they will respond to PharmaCyte’s previously

    Read more
  • 2:55 PM

    BEDMINSTER, N.J., Sept. 13, 2016, MTNB, (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, today announced the final closing of an $8.0 million private placement equity financing, which represents the full amount of the offering. The Company sold to accredited investors an aggregate of 1,600,000 Series A Preferred Shares at a purchase

    Read more
  • 3:22 PM

    ACKSONVILLE, Florida, September 6, 2016, TPIV, /PRNewswire/ — TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today issued a shareholder update regarding significant recent financial, clinical and regulatory milestones achieved, as well as an outlook on future catalysts. Dear Shareholders: We believe recent events have been transformative for TapImmune. We believe we are now funded to execute on the 4 Phase

    Read more
  • 3:23 PM

    LAGUNA HILLS, Calif., Sept. 01, 2016, PMCB, (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided an update on its program for developing treatments for serious brain cancers that involve constituents of the Cannabis plant. These Cannabis-based cancer therapies, like PharmaCyte’s pancreatic cancer therapy, will involve the use of its Cell-in-a-Box® technology. The cancer “prodrug” that will be activated

    Read more
  • 2:45 PM

    Oct 06, 2014 (eTeligis.com via COMTEX) — ANNAPOLIS, MD, United States, via ETELIGIS INC., 10/06/2014 – – Global Equity International, Inc. (OTCQB: GEQU), and its fully owned subsidiary, Global Equity Partners, Plc., a business consulting services firm to small and medium sized businesses worldwide, today announced that it has signed an agreement with Duo World Inc., a software company with subsidiaries in Sri Lanka, Singapore and India. Global Equity International Inc. through its subsidiary Global Equity Partners Plc. will assist

    Read more
Public Wire Banner